Levofolinic Acid Medac (Levoleucovorin Disodium)

Levoleucovorin disodium is a reduced folate that bypasses the dihydrofolate reductase step, directly replenishing tetrahydrofolate stores. This restores DNA and RNA synthesis in healthy cells, counteracting the inhibition caused by antifolate drugs such as methotrexate and 5‑fluorouracil.

The specific dose and infusion schedule are determined by the prescribing oncologist based on the chemotherapy regimen, patient weight, renal function, and treatment protocol. Dosage should always follow the healthcare professional’s instructions.

Safety data are limited, and the drug should only be used during pregnancy or lactation when the potential benefit outweighs any possible risk to the fetus or infant. The prescribing physician must evaluate the individual situation.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Levofolinic Acid Medac (levoleucovorin) is the reduced folate form most commonly used for methotrexate and 5‑fluorouracil rescue. Compared with calcium folinate, it offers similar efficacy but may have different solubility and stability profiles, making it suitable for specific intravenous formulations.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the administration protocol.

Levofolinic Acid Medac is given by intravenous infusion, typically over a short period as directed by the treatment protocol. The infusion rate and timing relative to chemotherapy agents are determined by the oncologist to achieve optimal rescue effect.

Serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment, pulmonary edema, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Prompt medical attention is required if any of these events occur.

Patients with known hypersensitivity to levoleucovorin or any component of the formulation should avoid the drug. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be used only when the clinical benefit justifies potential risks.